Nivolumab toxicity
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
Nivolumab toxicity. Peripheral adverse events, Guillain Barre syndrome (GBS), Hypokalaemic paralysis. Fully referenced neurology checklist.
Peripheral neurological features
- Peripheral adverse events
- Guillain Barre syndrome (GBS)
- Hypokalaemic paralysis
- Myasthenia gravis (MG)
- Lambert Eaton myasthenic syndrome (LEMS)
- Myositis
- Rhabdomyolysis
Central neurological features
Locked: subscribe to see this section.
Endocrine features
Locked: subscribe to see this section.
Dermatological features
Locked: subscribe to see this section.
Cardiac features
Locked: subscribe to see this section.
Renal features
Locked: subscribe to see this section.
Gastrointestinal features
Locked: subscribe to see this section.
Other features
Locked: subscribe to see this section.
References
- Hottinger AF. Neurologic complications of immune checkpoint inhibitors. Curr Opin Neurol 2016; 29:806-812.
- Izzedine H, Mateus C, Boutros C, et al. Renal effects of immune checkpoint inhibitors. Nephrol Dial Transplant 2017; 32:936-942.
- Supakornnumporn S, Katirji B. Guillain-Barré syndrome triggered by immune checkpoint inhibitors: a case report and literature review. J Clin Neuromuscul Dis 2017; 19:80-83.
- Barbacki A, Maliha PG, Hudson M, Small D. A case of severe pembrolizumab-induced neutropenia. Anticancer Drugs 2018; 29:817-819.
- Shirai T, Sano T, Kamijo F, et al. Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma. Jpn J Clin Oncol 2016; 46:86-88.
- And 33 more. Subscribe to see the full list
